CFCindy Fishman

Cindy Fishman

*This is an algorithmically generated author record based on publicly available information.

Cindy Fishman has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of Biomarkers to Detect Early Prothrombotic Imbalance in Rat Models of Hypercoagulability Induced by Thromboplastin Infusion and Hypofibrinolysis Induced by Tranexamic Acid

    by Marjory B. Brooks, Cindy E. Fishman, Mohanapriya Kamalakannan, Paula Katavolos, Claire E. O’bRien, Jennifer B. Pierson, Florence Poitout-Belissent, Michael K. Pugsley, Kurex Sidik, Brett R. Winters, et al.

    Thrombotic complications including myocardial infarction, stroke, venous thrombosis and pulmonary thromboembolism are common causes of drug attrition often discovered at late stages of drug development. Current nonclinical safety assessments include screening tests that detect hemorrhagic complications but do not identify conditions signaling a risk of thrombosis. Our study aimed to identify sensitive tests for detecting prothrombotic imbalance, without overt thrombosis, for use in early nonclinical drug safety assessments in rodents. Sprague Dawley rats were administered different doses of thromboplastin or tranexamic acid to induce variable intensity hypercoagulable or hypofibrinolytic states, respectively. A panel of functional and quantitative assays measuring hemostatic proteins and pathways were evaluated, in concert with traditional coagulation screening tests and blood cell counts. Profound changes were observed with different patterns of test abnormalities for the different stimuli. Measurements of D-dimer and thrombin antithrombin complex concentrations, plasminogen activator inhibitor-1 and Factor VIIa activity were among the most sensitive tests of hypercoagulability. In contrast, hypofibrinolysis was best characterized in a kinetic, turbidimetric assay. Traditional coagulation screening tests were relatively insensitive, and no single test defined the cause of prothrombotic imbalance. Our results demonstrate that customized biomarker panels can detect early drug-induced prothrombotic states in rats arising from distinct mechanisms.


  • Open Access

    Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax

    by Jamese J. Hilliard, Charles Jakielaszek, Frank Mannino, Mohammad Hossain, Lian Qian, Cindy Fishman, Samandra Demons, Jeremy Hershfield, Carl Soffler, Riccardo Russo, et al.

    Bacillus anthracis is a Gram-positive Centers for Disease Control and Prevention category “A” biothreat pathogen. Without early treatment, inhalation of anthrax spores with progression to inhalational anthrax disease is associated with high fatality rates. Gepotidacin is a novel first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is being evaluated for use against biothreat and conventional pathogens. Gepotidacin selectively inhibits bacterial DNA replication via a unique binding mode and has in vitro activity against a collection of B. anthracis isolates including antibacterial-resistant strains, with the MIC 90 ranging from 0.5 to 1 µg/mL. In vivo activity of gepotidacin was also evaluated in the New Zealand White rabbit model of inhalational anthrax. The primary endpoint was survival, with survival duration and bacterial clearance as secondary endpoints. The trigger for treatment was the presence of anthrax protective antigen in serum. New Zealand White rabbits were dosed intravenously for 5 days with saline or gepotidacin at 114 mg/kg/d to simulate a dosing regimen of 1,000 mg intravenous (i.v.) three times a day (TID) in humans. Gepotidacin provided a survival benefit compared to saline control, with 91% survival ( P -value: 0.0001). All control animals succumbed to anthrax and were found to be blood- and organ culture-positive for B. anthracis . The novel mode of action, in vitro microbiology, preclinical safety, and animal model efficacy data, which were generated in line with Food and Drug Administration Animal Rule, support gepotidacin as a potential treatment for anthrax in an emergency biothreat situation.


  • Open Access

    A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937

    by Paul D. Benn, Ying Zhang, Lesley Kahl, Thomas J. Greene, Veronica Bainbridge, Cindy Fishman, Bo Wen, Martin Gartland

    We report the safety and pharmacokinetic properties of the HIV‐1 maturation inhibitor GSK3739937 (GSK'937) in healthy participants. This was a phase I, first‐in‐human, double‐blind, randomized, placebo‐controlled, single‐ (part 1) and multiple‐ (part 2) dose escalation study with an additional open‐label relative bioavailability and food effect study (part 3). Participants received oral ascending single doses (10–800 mg) in part 1, up to 18 once‐daily 25‐ to 100‐mg or 3 once‐weekly 500‐mg doses in part 2, and single 100‐mg doses as powder‐in‐bottle or tablet (in fed and fasted states) formulations in part 3. Primary and secondary objectives were safety and pharmacokinetic assessments, respectively. Ninety‐one participants were enrolled; 38 reported 81 total adverse events (AEs). All AEs in participants receiving GSK'937 were grade 1 or 2 and resolved during the study. Most drug‐related AEs were gastrointestinal (14/17, 82%). The terminal phase half‐life of GSK'937 was ~3 days for all doses following single and repeat dosing. Geometric mean maximum concentration and total drug exposures exhibited dose‐proportional increases during part 1. Accumulation in exposure following repeat dosing was 6‐ to 7‐fold with daily dosing and ~1.7‐fold after weekly treatment, as expected due to the long half‐life. Bioavailability of GSK'937 after a meal was 1.35‐ to 1.40‐fold greater as a tablet versus powder‐in‐bottle and >2‐fold higher in fed versus fasted states when provided as a tablet. No unexpected or dose‐limiting safety events occurred. Pharmacokinetic parameters of long half‐life and accumulation of exposure following repeat dosing suggest the potential for weekly oral dosing. ClinicalTrials.gov identifier: NCT04493684.


  • Open Access

    Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge

    by Charles Jakielaszek, Jamese J. Hilliard, Frank Mannino, Mohammad Hossain, Lian Qian, Cindy Fishman, Ying-Liang Chou, Lisa Henning, Joseph Novak, Samandra Demons, et al.

    Francisella tularensis ( F. tularensis ) is a Centers for Disease Control (CDC) category “A” Gram-negative biothreat pathogen. Inhalation of F. tularensis can cause pneumonia and respiratory failure and is associated with high mortality rates without early treatment.


  • Open Access

    Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats

    by Cindy Fishman, Jessica M. Caverly Rae, Lorraine M. Posobiec, Susan B. Laffan, Steven A. Lerman, Neil Pearson, Salim Janmohamed, Etienne Dumont, Deatra Nunn-Floyd, Dinesh J. Stanislaus

    Fluoroquinolone use in children is limited due to its potential toxicity and negative effects on skeletal development, but the actual effects/risks of fluoroquinolones on bone growth and the mechanisms behind fluoroquinolone-driven arthropathy remain unknown. Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic with a unique mechanism of action that is not anticipated to have the same risks to bone growth as those of fluoroquinolones.


  • Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague

    by Charles Jakielaszek, Mohammad Hossain, Lian Qian, Cindy Fishman, Katherine Widdowson, Jamese J. Hilliard, Frank Mannino, Aparna Raychaudhuri, Elisabeth Carniel, Samandra Demons, et al.

    Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has the potential to treat a number of bacterial diseases. Development of this new agent to treat pneumonic plague caused by Yersinia pestis depends on the U.S. Food and Drug Administration Animal Rule testing pathway, as testing in humans is not feasible. Here, preclinical studies were conducted in the African green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin. AGMs infected with Y. pestis were dosed intravenously with gepotidacin (48, 36, or 28 milligrams/kilogram per day) for 10 days to provide a plasma concentration that would support a rationale for a 1000 mg twice or thrice daily intravenous dose in humans or saline as a control. The primary end point was AGM survival with predefined euthanasia criteria. Secondary end points included survival duration and bacterial clearance. Gepotidacin showed activity in vitro against diverse Y. pestis isolates including antibiotic-resistant strains. All control animals in the inhalational plague studies succumbed to plague and were blood culture and organ culture positive for Y. pestis . Gepotidacin provided a 75 to 100% survival benefit with all dose regimens. All surviving animals were blood culture and organ culture negative for Y. pestis . Our randomized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with the in vitro Y. pestis susceptibility data support the use of gepotidacin as a treatment for pneumonic plague caused by Y. pestis .